HMO Prescription Drug Coverage and Formularies

Prescription drug benefits within Health Maintenance Organization plans operate through a structured tier system called a formulary — a managed list of covered medications that directly determines what members pay at the pharmacy counter. Understanding how formularies are built, updated, and enforced is essential for anyone evaluating HMO plan options or managing chronic medication needs. This page covers formulary structure, tier mechanics, coverage boundaries, and the decision points that determine whether a specific drug is covered, excluded, or subject to special authorization.

Definition and scope

A formulary is the official list of prescription drugs that an HMO plan covers, developed and maintained by a Pharmacy and Therapeutics (P&T) committee composed of physicians and pharmacists. The committee reviews clinical evidence and cost data to determine which drugs earn coverage and at what cost-sharing level.

Formularies are plan-specific — two HMO products sold by the same insurer in the same state may list different drugs or assign identical drugs to different cost tiers. Under the Affordable Care Act, all plans sold on the individual and small-group markets must cover at least one drug in every United States Pharmacopeia category and class, establishing a minimum floor but allowing significant variation above it (45 CFR § 156.122).

Scope is national in concept but local in execution. A formulary applies only to medications dispensed through the plan's contracted pharmacy network. Filling a prescription at an out-of-network pharmacy generally produces no coverage benefit in a standard HMO — a structural difference from PPO plans, which typically reimburse out-of-network pharmacy purchases at a reduced rate. For a full comparison of how HMO cost-sharing mechanisms differ across plan types, see HMO Copays, Coinsurance, and Cost Sharing.

How it works

Most HMO formularies organize covered drugs into four or five tiers, with cost-sharing rising at each level:

1. Tier 1 — Preferred Generics: Lowest copay, typically $0–$15 per 30-day supply. Generic drugs bioequivalent to brand-name counterparts.
2. Tier 2 — Non-Preferred Generics / Preferred Brands: Moderate copay, commonly $25–$50. Includes brand drugs with strong formulary positioning due to manufacturer pricing agreements.
3. Tier 3 — Non-Preferred Brands: Higher cost-sharing, often $60–$100 or a coinsurance percentage. Brands where a lower-cost equivalent exists on the formulary.
4. Tier 4 — Specialty Drugs: The highest cost-sharing tier, frequently structured as coinsurance (20–33%) rather than a flat copay. Biologics, injectable therapies, and complex chronic-condition medications dominate this tier.
5. Tier 5 — Select Care / Preventive Zero-Cost: A growing sub-tier used to place preventive medications required at no cost under ACA Section 2713 and identified by the U.S. Preventive Services Task Force.

Beyond tier placement, several utilization management tools govern dispensing:

• Prior Authorization (PA): The prescriber must submit clinical justification before the plan approves coverage. Common for Tier 3 and Tier 4 drugs and most specialty medications.
• Step Therapy: The plan requires a member to try a lower-cost drug first. If that drug fails clinically, the plan may then approve the originally requested medication.
• Quantity Limits: Maximum supply per fill, usually aligned with FDA-approved dosing guidelines, to prevent over-dispensing.
• Days Supply Restrictions: Mail-order pharmacies contracted by the HMO often allow 90-day supplies at reduced per-unit cost, compared with 30-day retail fills.

Formularies are updated periodically — at minimum annually during plan renewal cycles, and sometimes mid-year when a drug is recalled, loses patent protection, or when a manufacturer changes pricing terms. Mid-year removals are subject to federal transition-of-care protections requiring plans to provide 60 days' notice to affected members (45 CFR § 156.122(c)).

The complete resource on how HMO plans coordinate care broadly — including pharmacy networks — is at How HMO Plans Work.

Common scenarios

Chronic condition management: A member with Type 2 diabetes may find metformin on Tier 1 at no cost-sharing, while a newer branded GLP-1 receptor agonist such as a semaglutide-class drug sits on Tier 4 with 25% coinsurance. Step therapy may require documented metformin failure before the plan authorizes the higher-cost option.

Generic substitution at the counter: A prescriber writes for a brand-name drug. The pharmacy's dispensing system automatically proposes the generic equivalent. If the member accepts the substitution, Tier 1 pricing applies. If the prescriber has indicated "dispense as written," the brand is dispensed at Tier 3 pricing even if a generic is available.

Specialty pharmacy carve-out: HMOs routinely require specialty-tier drugs to be filled exclusively through a designated specialty pharmacy — not a retail chain. Filling at an unauthorized pharmacy produces a coverage denial regardless of formulary status.

Formulary exclusion: A drug may not appear on the formulary at all. In that case, the member's only pathway to coverage is a formulary exception request, which requires clinical documentation that no formulary alternative is medically appropriate. The plan must respond to urgent exception requests within 72 hours under CMS guidelines (42 CFR § 423.568, applicable to Medicare Part D, with parallel protections under state law for commercial plans).

Decision boundaries

The HMO authority index covers the full framework of managed care structures, within which pharmacy benefit design sits at the intersection of clinical protocol and cost management. Four decision boundaries define whether and at what cost a specific drug is covered:

Formulary status vs. non-formulary status
A drug listed on the formulary carries defined cost-sharing. A non-formulary drug requires an exception process and carries no guarantee of approval. Members switching to an HMO from a PPO plan should verify that their existing medications appear on the new plan's formulary before the effective date.

In-network pharmacy vs. out-of-network pharmacy
Standard HMO rules treat pharmacy network participation the same as provider network participation. A covered drug filled at an out-of-network pharmacy is treated as a non-covered service — the member bears the full cost.

Prior authorization granted vs. denied
If a PA request is denied, the member has the right to an internal appeal and, if that fails, an external review. Federal parity rules and state-level HMO regulations govern timelines. The process for challenging a denial is detailed at How to Appeal an HMO Claim Denial.

Specialty tier coinsurance vs. fixed copay
For high-cost specialty drugs, coinsurance structures mean out-of-pocket exposure scales with drug cost. A medication priced at $8,000 per 30-day supply at 25% coinsurance produces a $2,000 member liability — capped only by the plan's annual out-of-pocket maximum. Plans using flat copays for specialty drugs ($150–$250 range) limit this exposure regardless of list price, making the coinsurance-versus-copay distinction financially significant for members on high-cost biologics.

References

• U.S. Department of Health and Human Services — Affordable Care Act Overview
• Electronic Code of Federal Regulations — 45 CFR § 156.122: Formulary Requirements for QHPs
• Electronic Code of Federal Regulations — 42 CFR § 423.568: Medicare Part D Coverage Determination Timeframes
• Centers for Medicare & Medicaid Services — Prescription Drug Coverage Standards
• U.S. Pharmacopeia — Drug Classification Framework
• U.S. Preventive Services Task Force — ACA Preventive Services Mandate

The law belongs to the people. Georgia v. Public.Resource.Org, 590 U.S. (2020)